Floatz logo

Azacitidine

Myelodysplastic Syndrome With Excess Blasts-2

Aptose Biosciences Inc.Small moleculePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Myelodysplastic Syndrome With Excess Blasts-2 cohort.

Asset / SponsorPhaseRating
Fludarabine
Sumithira Vasu
Phase 2BB
Gilteritinib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3BB
Cytarabine
Sumithira Vasu
Phase 2BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2B
Midostaurin
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3B

View all 28 →

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Active
BBB
Indicative · Phase 2
73 / 100
View asset →
acute erythroid leukemiaActive
BB
Indicative · Phase 2
71 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesActive
BB
Indicative · Phase 2
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →